The steady stream of positive news coming from the EU's CHMP today did not extend to Isis Pharmaceuticals (NASDAQ:IONS) and Sanofi (NYSE:SNY). Unfortunately, the duo's drug Kynamro, which is FDA-approved for the treatment of Homozygous Familial Hypercholesterolaemia in the United States, failed to win the green light from the CHMP for the second time.
What does this mean for Isis and Sanofi? And does this make Isis more vulnerable to its competitor Aegerion Pharmaceuticals (NASDAQ:AEGR)? Health-care analyst Max Macaluso dives into these issues in the following video.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.